Oric Pharmaceuticals
Danial Barati, PhD, is an accomplished in vivo Pharmacology Research Scientist at ORIC Pharmaceuticals Inc. since October 2022, following a role as an Animal Research Scientist at Zogenix, Inc. from December 2021 to September 2022. Prior to that, Danial served as a Postdoctoral Research Fellow at Stanford University from July 2017 to December 2021 and as a Lab Manager at the University of South Carolina's polymer engineering and biomedical engineering lab from August 2010 to July 2017, mentoring over 20 undergraduate and graduate students. Danial's academic credentials include a Doctor of Philosophy in Chemical Engineering from the University of South Carolina, a Master's Degree in Chemical/Biomedical Engineering from the same institution, and a Bachelor of Science in Chemical Engineering from the University of Tehran.
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.